{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T21:48:58Z","timestamp":1776376138694,"version":"3.51.2"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse (NIDA)","doi-asserted-by":"publisher","award":["R01-DA021525"],"award-info":[{"award-number":["R01-DA021525"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Michael Smith Foundation for Health Research (MSFHR) post-doctoral fellowship award and a Canada Addiction Medicine Research Fellowship","award":["R25-DA037756"],"award-info":[{"award-number":["R25-DA037756"]}]},{"name":"NIH","award":["R01-DA021525"],"award-info":[{"award-number":["R01-DA021525"]}]},{"name":"Canadian Institutes of Health Research New Investigator Award (CIHR)"},{"name":"MSFHR Scholar Award"},{"name":"CIHR New Investigator Award"},{"name":"MSFHR Scholar Award"},{"name":"Tier 1 Canada Research Chair in Inner City Medicine"},{"DOI":"10.13039\/501100004726","name":"British Columbia Ministry of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004726","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIDA","award":["R01-DA036307"],"award-info":[{"award-number":["R01-DA036307"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","ijdp.org","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.drugpo.2017.03.008","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T22:47:09Z","timestamp":1493160429000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Unintended impacts of regulatory changes to British Columbia Methadone Maintenance Program on addiction and HIV-related outcomes: An interrupted time series analysis"],"prefix":"10.1016","volume":"45","author":[{"given":"M. Eugenia","family":"Soc\u00edas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiru","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Shoveller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Montaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-J.","family":"Milloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugpo.2017.03.008_bib0005","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S2352-3018(15)00129-0","article-title":"Effect of low-threshold methadone maintenance therapy for people who inject drugs on HIV incidence in Vancouver, BC, Canada: An observational cohort study","volume":"2","author":"Ahamad","year":"2015","journal-title":"The Lancet HIV"},{"issue":"Suppl. 1","key":"10.1016\/j.drugpo.2017.03.008_bib0010","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/QAI.0b013e318209751e","article-title":"HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine\/naloxone treatment within HIV clinical care settings: Results from a multisite study","volume":"56","author":"Altice","year":"2011","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0015","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3851\/IMP2084","article-title":"Beyond virological suppression: The role of adherence in the late HAART era","volume":"17","author":"Ammassari","year":"2012","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0020","unstructured":"British Columbia Harm Reduction Program (January 1, 2014). Upcoming changes to BC methadone maintenance program. In Toward the heart. BC Centre for Disease Control."},{"key":"10.1016\/j.drugpo.2017.03.008_bib0025","series-title":"Opioid overdose prevention & response in Canada","author":"Carter","year":"2013"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0030","series-title":"Methadone maintenance treatment policy guide","author":"College of Pharmacists of British Columbia","year":"2013"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0035","unstructured":"College of Pharmacists of British Columbia (2013b). Professional practice policy No. 66: Methadone maintenance treatment."},{"key":"10.1016\/j.drugpo.2017.03.008_bib0040","unstructured":"College of Pharmacists of British Columbia (2013c). Professional practice policy No. 71: delivery of methadone for maintenance."},{"key":"10.1016\/j.drugpo.2017.03.008_bib0045","series-title":"Methadone and buprenorphine: Clinical practice guideline for opioid use disorder","author":"College of Physicians and Surgeons of British Columbia","year":"2016"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0050","unstructured":"College of Physicians and Surgeons of British Columbia (January 2014). An important update from the methadone maintenance program."},{"key":"10.1016\/j.drugpo.2017.03.008_bib0055","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMra1508490","article-title":"Relationship between nonmedical prescription-opioid use and heroin use","volume":"374","author":"Compton","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0060","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/oxfordjournals.aje.a008806","article-title":"Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population","volume":"143","author":"De Irala","year":"1996","journal-title":"American Journal of Epidemiology"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0065","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(11)61138-0","article-title":"Extent of illicit drug use and dependence, and their contribution to the global burden of disease","volume":"379","author":"Degenhardt","year":"2012","journal-title":"The Lancet"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0070","first-page":"409","article-title":"Testing for serial correlation in least squares regression. I","volume":"37","author":"Durbin","year":"1950","journal-title":"Biometrika"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0075","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0740-5472(99)00008-2","article-title":"Three oral formulations of methadone. A clinical and pharmacodynamic comparison","volume":"17","author":"Gourevitch","year":"1999","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0080","first-page":"CD004145","article-title":"Oral substitution treatment of injecting opioid users for prevention of HIV infection","author":"Gowing","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13011-016-0048-3","article-title":"Patient perspectives of methadone formulation change in British Columbia, Canada : Outcomes of a provincial survey","volume":"11","author":"Greer","year":"2016","journal-title":"Substance Abuse Treatment Prevention and Policy"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0090","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jclinepi.2004.04.002","article-title":"A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV","volume":"57","author":"Grossberg","year":"2004","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0095","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jclinepi.2014.12.018","article-title":"Interrupted time series analysis in drug utilization research is increasing: Systematic review and recommendations","volume":"68","author":"Jandoc","year":"2015","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0100","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.2105\/AJPH.2014.301966","article-title":"Determinants of increased opioid-related mortality in the United States and Canada, 1990-2013: A systematic review","volume":"104","author":"King","year":"2014","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0105","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/ije\/28.3.514","article-title":"The validity of drug users\u2019 self-reports in a non-treatment setting: Prevalence and predictors of incorrect reporting methadone treatment modalities","volume":"28","author":"Langendam","year":"1999","journal-title":"International Journal of Epidemiology"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0110","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/cid\/ciw416","article-title":"Impact of Opioid Substitution Therapy on Antiretroviral Therapy Outcomes: A Systematic Review and Meta-Analysis","volume":"63","author":"Low","year":"2016","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0115","unstructured":"Luce, J., & Strike, C. (April 2011). A cross-Canada scan of methadone maintenance treatment policy developments. A report prepared for the Canadian executive council on addictions."},{"key":"10.1016\/j.drugpo.2017.03.008_bib0120","doi-asserted-by":"crossref","first-page":"e5945","DOI":"10.1136\/bmj.e5945","article-title":"Opiate substitution treatment and HIV transmission in people who inject drugs: Systematic review and meta-analysis","volume":"345","author":"MacArthur","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0125","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0130","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.socscimed.2015.04.008","article-title":"Negotiating structural vulnerability following regulatory changes to a provincial methadone program in Vancouver, Canada: A qualitative study","volume":"133","author":"McNeil","year":"2015","journal-title":"Social Science & Medicine"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0135","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/QAD.0000000000000642","article-title":"The causal effect of opioid substitution treatment on HAART medication refill adherence","volume":"29","author":"Nosyk","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0140","unstructured":"Office of the Provincial Health Officer (July 2015). BC opioid substitution treatment system, performance measures 2013\/2014. British Columbia Ministry of Health."},{"key":"10.1016\/j.drugpo.2017.03.008_bib0145","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.drugpo.2015.04.015","article-title":"An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential","volume":"26","author":"Perlman","year":"2015","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13011-016-0053-6","article-title":"Factors associated with inability to access addiction treatment among people who inject drugs in Vancouver, Canada","volume":"11","author":"Prangnell","year":"2016","journal-title":"Substance Abuse Treatment Prevention and Policy"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0155","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0740-5472(96)00099-2","article-title":"Change intolerance to shifts in methadone formulation: A preliminary investigation","volume":"13","author":"Silver","year":"1996","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0160","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/j.1360-0443.1992.tb02662.x","article-title":"The consequences of a change in formulation of methadone prescribed in a drug clinic","volume":"87","author":"Steels","year":"1992","journal-title":"British Journal of Addiction"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0165","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jama.280.6.547","article-title":"Barriers to use of free antiretroviral therapy in injection drug users","volume":"280","author":"Strathdee","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0170","series-title":"Drug situation in Vancouver","author":"Urban Health Research Initiative","year":"2013"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0175","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10461-014-0927-4","article-title":"Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART)","volume":"19","author":"Viswanathan","year":"2015","journal-title":"AIDS and Behavior"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0180","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies\u2013tackling the opioid-overdose epidemic","volume":"370","author":"Volkow","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0185","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research","volume":"27","author":"Wagner","year":"2002","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0190","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1001\/jama.300.5.550","article-title":"Highly active antiretroviral therapy and survival in HIV-infected injection drug users","volume":"300","author":"Wood","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.drugpo.2017.03.008_bib0195","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jclinepi.2008.08.007","article-title":"Methods for estimating confidence intervals in interrupted time series analyses of health interventions","volume":"62","author":"Zhang","year":"2009","journal-title":"Journal of Clinical Epidemiology"}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395917300828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395917300828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T10:51:02Z","timestamp":1538045462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395917300828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":39,"alternative-id":["S0955395917300828"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2017.03.008","relation":{},"ISSN":["0955-3959"],"issn-type":[{"value":"0955-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unintended impacts of regulatory changes to British Columbia Methadone Maintenance Program on addiction and HIV-related outcomes: An interrupted time series analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Drug Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugpo.2017.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}